Abdellaoui, M. ; Baillon, A. ; Placido, L. ; Wakker, P.P. The rich domain of uncertainty: source functions and their experimental implementation. 2011 Am. Econ. Rev.. 101 695-723
Abdellaoui, M. ; Barrios, C. ; Wakker, P.P. Reconciling introspective utility with revealed preference: experimental arguments based on prospect theory. 2007 J. Econom.. 138 356-378
Abdellaoui, M. ; Bleichrodt, H. ; l'Haridon, O. A tractable method to measure utility and loss aversion under prospect theory. 2008 J. Risk Uncertain. 36 245-266
- Atkinson, A.B. On the measurement of inequality. 1970 J. Econ. Theory. 2 244-263
Paper not yet in RePEc: Add citation now
Attema, A.E. ; Brouwer, W.B. ; l'Haridon, O. ; Pinto, J.L. An elicitation of utility for quality of life under prospect theory. 2016 J. Health Econ.. 48 121-134
Attema, A.E. ; Frasch, J.J. ; L'haridon, O. Multivariate risk preferences in the quality-adjusted life year model. 2022 Health Econ.. 31 382-398
Attema, A.E. ; l'Haridon, O. ; van de Kuilen, G. Measuring multivariate risk preferences in the health domain. 2019 J. Health Econ.. 64 15-24
Attema, A.E. ; Werner, B.F.B. ; Olivier, l.H. Prospect theory in the health domain: a quantitative assessment. 2013 J. Health Econ.. 32 1057-1065
Barsky, R.B. ; Juster, F.T. ; Kimball, M.S. ; Shapiro, M.D. Preference parameters and behavioral heterogeneity: an experimental approach in the health and retirement study. 1997 Q. J. Econ.. 112 537-579
Bleichrodt, H. ; Abellan-Perpiñan, J.M. ; Pinto-Prades, J.L. ; Mendez-Martinez, I. Resolving inconsistencies in utility measurement under risk: tests of generalizations of expected utility. 2007 Manage Sci.. 53 469-482
Bleichrodt, H. ; Crainich, D. ; Eeckhoudt, L. The effect of comorbidities on treatment decisions. 2003 J. Health Econ.. 22 805-820
Bleichrodt, H. ; Miyamoto, J. A characterization of quality-adjusted life-years under cumulative prospect theory. 2003 Math. Oper. Res.. 28 181-193
Bleichrodt, H. ; Pinto, J.L. ; Wakker, P.P. Making descriptive use of prospect theory to improve the prescriptive use of expected utility. 2001 Manage Sci.. 47 1498-1514
Bleichrodt, H. ; Quiggin, J. Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis?. 1999 J. Health Econ.. 18 681-708
- Bosk, C.L. Obtaining voluntary consent for research in desperately ill patients. 2002 Med. Care. 40 -
Paper not yet in RePEc: Add citation now
Brocas, I. ; Carrillo, J.D. ; Giga, A. ; Zapatero, F. Risk aversion in a dynamic asset allocation experiment. 2019 J. Financ. Quant. Anal.. 54 2209-2232
- Brock, D.W. ; Daniels, N. ; Neumann, P.J. ; Siegel, J.E. Ethical and Distributive Considerations. Cost-Effectiveness in Health and Medicine. 2016 Oxford University Press:
Paper not yet in RePEc: Add citation now
- Centers for Disease Control and Prevention. (June 24, 2022). "Genetic counseling." from https://www.cdc.gov/genomics/gtesting/genetic_counseling.htm.
Paper not yet in RePEc: Add citation now
- Chai, T. ; Draxler, R.R. Root mean square error (RMSE) or mean absolute error (MAE)? – Arguments against avoiding RMSE in the literature. 2014 Geosci. Model Dev.. 7 1247-1250
Paper not yet in RePEc: Add citation now
- Chen, T.H.-H. ; Yen, M.-F. ; Tung, T.-H. A computer simulation model for cost–effectiveness analysis of mass screening for Type 2 diabetes mellitus. 2001 Diabetes Res. Clin. Pract.. 54 37-42
Paper not yet in RePEc: Add citation now
Chetan, D. ; Eckel, C.C. ; Johnson, C.A. ; Rojas, C. Eliciting risk preferences: when is simple better?. 2010 J. Risk Uncertain. 41 219-243
Cohen, J. ; Ericson, K.M. ; Laibson, D. ; White, J.M. Measuring time preferences. 2020 J. Econ. Lit.. 58 299-347
Cohen, M.D. (1995). "Risk-aversion concepts in expected-and non-expected-utility models." Non-Expected Utility and Risk Management: A Special Issue of the Geneva Papers on Risk and Insurance Theory: 73–91.
Cookson, R. ; Drummond, M. ; Weatherly, H. Explicit incorporation of equity considerations into economic evaluation of public health interventions. 2009 Health Econ. Policy Law. 4 231-245
Delprat, G. ; Leroux, M.L. ; Michaud, P.C. Evidence on individual preferences for longevity risk. 2016 J. Pension Econ. Financ.. 15 160-179
Doctor, J.N. ; Bleichrodt, H. ; Miyamoto, J. ; Temkin, N.R. ; Dikmen, S. A new and more robust test of QALYs. 2004 J. Health Econ. 23 353-367
Drichoutis, A.C. ; Lusk, J.L. What can multiple price lists really tell us about risk preferences?. 2016 J. Risk Uncertain. 53 89-106
- Drummond, M. ; Brixner, D. ; Gold, M. ; Kind, P. ; McGuire, A. ; Nord, E. Toward a consensus on the QALY. 2009 Value Health. 12 S31-S35
Paper not yet in RePEc: Add citation now
Eeckhoudt, L. Expected utility theory—is it normative or simply" practical"?. 1996 BMC Med. Inf. Decis. Mak.. 16 12-13
- Food and Drug Administration. (January 23, 2023). "Right to try." from https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try.
Paper not yet in RePEc: Add citation now
Franken, M. ; Stolk, E. ; Scharringhausen, T. ; de Boer, A. ; Koopmanschap, M. A comparative study of the role of disease severity in drug reimbursement decision making in four European countries. 2015 Health Policy (New York). 119 195-202
Friedman, M. ; Savage, L.J. The utility analysis of choices involving risk. 1948 J. Political Econ.. 56 279-304
- Galizzi, M.M. ; Miraldo, M. ; Stavropoulou, C. In sickness but not in wealth: field evidence on patients' risk preferences in financial and health domains. 2016 Med. Decis. Mak.. 36 503-517
Paper not yet in RePEc: Add citation now
Garber, A.M. ; Phelps, C.E. Economic foundations of cost-effectiveness analysis. 1997 J. Health Econ.. 16 1-31
- Gæde, P. ; Johansen, P. ; Tikkanen, C.K. ; Pollock, R.F. ; Hunt, B. ; Malkin, S.J.P. Management of patients with type 2 diabetes with once-weekly semaglutide versus dulaglutide, exenatide ER, liraglutide and lixisenatide: a cost-effectiveness analysis in the Danish setting. 2019 Diabetes Ther.. 10 1297-1317
Paper not yet in RePEc: Add citation now
- Golan, L. ; Birkmeyer, J.D. ; Welch, H.G. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. 1999 Ann. Intern. Med.. 131 660-667
Paper not yet in RePEc: Add citation now
- Grima, D.T. ; Thompson, M.F. ; Sauriol, L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. 2007 Pharmacoeconomics. 25 253-266
Paper not yet in RePEc: Add citation now
Haigh, M.S. ; List, J.A. Do professional traders exhibit myopic loss aversion? An experimental analysis. 2005 J. Financ.. 60 523-534
- Halek, M. ; Eisenhauer, J.G. Demography of risk aversion. 2001 J. Risk Insur.. 68 1-24
Paper not yet in RePEc: Add citation now
- Harsanyi, J.C. Cardinal welfare, individualistic ethics, and interpersonal comparisons of utility. 1955 J. Political Econ.. 63 309-321
Paper not yet in RePEc: Add citation now
- Hines, E.A. ; Brown, G.E. The cold pressor test for measuring the reactibility of the blood pressure: data concerning 571 normal and hypertensive subjects. 1936 Am. Heart J.. 11 1-9
Paper not yet in RePEc: Add citation now
Hirth, R.A. ; Chernew, M.E. ; Miller, E. ; Fendrick, A.M. ; Weissert, W.G. Willingness to pay for a quality-adjusted life year: in search of a standard. 2000 BMC Med. Inf. Decis. Mak.. 20 332-342
Holt, C.A. ; Laury, S.K. Risk aversion and incentive effects: new data without order effects. 2005 Am. Econ. Rev.. 95 902-904
Holt, C.A. ; Laury, S.K. Risk aversion and incentive effects. 2002 Am. Econ. Rev.. 92 1644-1655
- Institute for Clinical Economic Review Oral Immunotherapy and Viaskin® Peanut for Peanut Allergy: Effectiveness and Value. 2019 Institute for Clinical and Economic Review: Boston, MA
Paper not yet in RePEc: Add citation now
- Johri, M. ; Norheim, O.F. Can cost-effectiveness analysis integrate concerns for equity? Systematic review. 2012 Int. J. Technol. Assess. Health Care. 28 125-132
Paper not yet in RePEc: Add citation now
Kahneman, D.J. ; Tversky, A. Prospect theory: an analysis of decision under risk. 1979 Econometrica. 47 363-391
- Kahneman, D.J. ; Tversky, A. The psychology of preferences. 1982 Sci. Am.. 246 160-173
Paper not yet in RePEc: Add citation now
Krieger, M. and T. Mayrhofer (2012). "Patient preferences and treatment thresholds under diagnostic risk." Ruhr Economic Paper(321).
- Lakdawalla, D.N. ; Doshi, J.A. ; Garrison, L.P. ; Phelps, C.E. ; Basu, A. ; Danzon, P.M. Defining elements of value in health care-a health economics approach: an ISPOR special task force report [3]. 2018 Value Health. 21 131-139
Paper not yet in RePEc: Add citation now
Lakdawalla, D.N. ; Phelps, C.E. A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE). 2022 Eur. J. Health Econ.. 23 433-451
- Lakdawalla, D.N. ; Phelps, C.E. Health technology assessment with diminishing returns to health: the Generalized Risk-Adjusted Cost Effectiveness (GRACE) approach. 2021 Value Health. 24 244-249
Paper not yet in RePEc: Add citation now
- Lakdawalla, D.N. ; Phelps, C.E. Health technology assessment with risk aversion in health. 2020 J. Health Econ.. 72 -
Paper not yet in RePEc: Add citation now
Lakdawalla, D.N. ; Phelps, C.E. The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) model for measuring the value of gains in health: an exact formulation. 2023 J. Benefit Cost. Anal.. 14 44-67
- Lakdawalla, D.N. ; Romley, J.A. ; Sanchez, Y. ; Maclean, J.R. ; Penrod, J.R. ; Philipson, T. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. 2012 Health Aff.. 31 676-682
Paper not yet in RePEc: Add citation now
- Langer, A.S. Side effects, quality-of-life issues, and trade-offs: the patient perspective. 2001 J. Natl. Cancer Inst.. 2001 125-129
Paper not yet in RePEc: Add citation now
Li, Z. ; Rohde, K.I.M. ; Wakker, P.P. Improving one's choices by putting oneself in others’ shoes – an experimental analysis. 2017 J. Risk Uncertain. 54 1-13
- Ma, J. ; Wan, X. ; Wu, B. The cost-effectiveness of lifestyle interventions for preventing diabetes in a health resource-limited setting. 2020 J. Diabetes Res.. 2020 -
Paper not yet in RePEc: Add citation now
Markowitz, H. Portfolio selection. 1952 J. Financ.. 7 77-91
- McNeil, B.J. ; Weichselbaum, R. ; Pauker, S.G. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. 1981 N. Engl. J. Med.. 305 982-987
Paper not yet in RePEc: Add citation now
Merton, R.C. Optimum consumption and portfolio rules in a continuous-time model. 1971 J. Econ. Theory. 3 373-413
Meyer, J. Representing risk preferences in expected utility based decision models. 2010 Ann. Oper. Res.. 176 179-190
- Miyamoto, J.M. ; Eraker, S.A. A multiplicative model of the utility of survival duration and health quality. 1988 J. Exp. Psychol. Gen.. 117 3-
Paper not yet in RePEc: Add citation now
Moffatt, P. ; Starmer, C. ; Sugden, R. ; Bardsley, N. ; Cubitt, R. ; Loomes, G. Experimental Economics: Rethinking the Rules. 2009 Princeton University Press:
- Neumann, P.J. ; Cohen, J.T. ; Weinstein, M.C. Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold. 2014 N. Engl. J. Med.. 371 796-797
Paper not yet in RePEc: Add citation now
- Nord, E. The relevance of health state after treatment in prioritising between different patients. 1993 J. Med. Ethics. 19 37-42
Paper not yet in RePEc: Add citation now
Nord, E. ; Johansen, R. Concerns for severity in priority setting in health care: a review of trade-off data in preference studies and implications for societal willingness to pay for a QALY. 2014 Health Policy (New York). 116 281-288
Nord, E. ; Johansen, R. Transforming EQ-5D utilities for use in cost–value analysis of health programs. 2015 Eur. J. Health Econ.. 16 313-328
Nord, E. ; Richardson, J. ; Street, A. ; Kuhse, H. ; Singer, P. Maximizing health benefits vs egalitarianism: an Australian survey of health issues. 1995 Soc. Sci. Med.. 41 1429-1437
Noussair, C.N. ; Trautmann, S.T. ; van de Kuilen, G. Higher order risk attitudes, demographics, and financial decisions. 2014 Rev. Econ. Stud.. 81 325-355
- Nurgat, Z.A. ; Craig, W. ; Campbell, N.C. ; Bissett, J.D. ; Cassidy, J. ; Nicolson, M.C. Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. 2005 Br. J. Cancer. 92 1001-1005
Paper not yet in RePEc: Add citation now
- Office of Technology Assessment (1992). Evaluation of the oregon medicaid proposal, US Congress, Office of Technology Assessment.
Paper not yet in RePEc: Add citation now
- Phelps, C.E. ; Lakdawalla, D.N. Methods to adjust willingness-to-pay measures for severity of illness. 2023 Value Health. 26 1003-1010
Paper not yet in RePEc: Add citation now
Prosser, L.A. ; Wittenberg, E. Do risk attitudes differ across domains and respondent types?. 2007 Med. Decis. Mak.. 27 281-287
- Raikou, M. ; McGuire, A. ; Colhoun, H. ; Betteridge, D. ; Durrington, P. ; Hitman, G. ; Neil, H. ; Livingstone, S. ; Charlton-Menys, V. ; Fuller, J. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). 2007 Diabetologia. 50 733-740
Paper not yet in RePEc: Add citation now
- Ramsey, S.D. ; Clarke, L.D. ; Roberts, C.S. ; Sullivan, S.D. ; Johnson, S.J. ; Liu, L.Z. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. 2008 Pharmacoeconomics.. 26 329-339
Paper not yet in RePEc: Add citation now
- Risebrough, N.A. ; Baker, T.M. ; Zhang, L. ; Ali, S.N. ; Radin, M. ; Dang-Tan, T. Lifetime cost-effectiveness of oral semaglutide versus dulaglutide and liraglutide in patients with type 2 diabetes inadequately controlled with oral antidiabetics. 2021 Clin. Ther.. 43 1812-1826
Paper not yet in RePEc: Add citation now
- Rosen, S. The value of changes in life expectancy. 1988 J. Risk Uncertain. 1 285-304
Paper not yet in RePEc: Add citation now
- Rouyard, T. ; Attema, A. ; Baskerville, R. ; Leal, J. ; Gray, A. Risk attitudes of people with ‘manageable'chronic disease: an analysis under prospect theory. 2018 Soc. Sci. Med.. 214 144-153
Paper not yet in RePEc: Add citation now
Saha, A. Expo-power utility: a ‘flexible'form for absolute and relative risk aversion. 1993 Am. J. Agric. Econ.. 75 905-913
- Seabury, S.A. ; Goldman, D.P. ; Maclean, J.R. ; Penrod, J.R. ; Lakdawalla, D.N. Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates. 2012 Health Aff.. 31 691-699
Paper not yet in RePEc: Add citation now
- Shafrin, J. ; Schwartz, T.T. ; Okoro, T. ; Romley, J.A. Patient versus physician valuation of durable survival gains: implications for value framework assessments. 2017 Value Health. 20 217-223
Paper not yet in RePEc: Add citation now
- Skedgel, C. ; Henderson, N. ; Towse, A. ; Mott, D. ; Green, C. Considering severity in health technology assessment: can we do better?. 2022 Value Health. 25 1399-1403
Paper not yet in RePEc: Add citation now
- Smerecnik, C.M. ; Mesters, I. ; Verweij, E. ; de Vries, N.K. ; de Vries, H. A systematic review of the impact of genetic counseling on risk perception accuracy. 2009 J. Genet. Couns.. 18 217-228
Paper not yet in RePEc: Add citation now
- Soares, M.O. Is the QALY blind, deaf and dumb to equity? NICE’s considerations over equity. 2012 Br. Med. Bull.. 101 17-31
Paper not yet in RePEc: Add citation now
- Stiggelbout, A.M. ; de Haes, J.C. Patient preference for cancer therapy: an overview of measurement approaches. 2001 J. Clin. Oncol.. 19 220-230
Paper not yet in RePEc: Add citation now
Stolk, E.A. ; Brouwer, W.B. ; Busschbach, J.J. Rationalising rationing: economic and other considerations in the debate about funding of Viagra. 2002 Health Policy (New York). 59 53-63
- Sulmasy, D.P. ; Astrow, A.B. ; He, M.K. ; Seils, D.M. ; Meropol, N.J. ; Micco, E. ; Weinfurt, K.P. The culture of faith and hope. 2010 Cancer. 116 3702-3711
Paper not yet in RePEc: Add citation now
- Tarn, D.M. ; Pletcher, M.J. ; Tosqui, R. ; Fernandez, A. ; Tseng, C.-h. ; Moriconi, R. ; Bell, D.S. ; Barrientos, M. ; Turner, J.A. ; Schwartz, J.B. Primary nonadherence to statin medications: survey of patient perspectives. 2021 Prev. Med. Rep.. 22 -
Paper not yet in RePEc: Add citation now
Tversky, A. ; Kahneman, D.J. Advances in prospect theory: cumulative representation of uncertainty. 1992 J. Risk Uncertain. 5 297-323
- Van Wilder, L. ; Rammant, E. ; Clays, E. ; Devleesschauwer, B. ; Pauwels, N. ; De Smedt, D. A comprehensive catalogue of EQ-5D scores in chronic disease: results of a systematic review. 2019 Qual. Life Res.. 28 3153-3161
Paper not yet in RePEc: Add citation now
- Wailoo, A. ; Tsuchiya, A. ; McCabe, C. Weighting must wait. 2009 Pharmacoeconomics.. 27 983-989
Paper not yet in RePEc: Add citation now
- Wan, W. ; Skandari, M.R. ; Minc, A. ; Nathan, A.G. ; Winn, A. ; Zarei, P. ; O'Grady, M. ; Huang, E.S. Cost-effectiveness of continuous glucose monitoring for adults with type 1 diabetes compared with self-monitoring of blood glucose: the DIAMOND randomized trial. 2018 Diabetes Care. 41 1227-1234
Paper not yet in RePEc: Add citation now
Ward, T. ; Mujica-Mota, R.E. ; Spencer, A.E. ; Medina-Lara, A. Incorporating equity concerns in cost-effectiveness analyses: a systematic literature review. 2022 Pharmacoeconomics.. 40 45-64
- Williams, A. Cost-effectiveness analysis: is it ethical?. 1992 J. Med. Ethics. 18 7-11
Paper not yet in RePEc: Add citation now